Skip to content
★ Sign in to follow
Jiangsu Yahong Meditech Co., Ltd. logo

Jiangsu Yahong Meditech Co., Ltd. Stock: price and insider trades · China

亚虹医药

CN·Mcap CN¥6.4BHealth Care

No insider purchase over the last 90 days. The latest, by PAN KE, was filed 19 Apr 2024.

Jiangsu Yahong Meditech Co., Ltd.: what insiders have been doing

Every trade that managers of Jiangsu Yahong Meditech Co., Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 4 November 2026, brought 4 filings signed by 2 insiders.

There is no open-market purchase to report; the filings show 4 sales worth €70k by 2 insiders. 孙巧玲 filed the largest sale, €26k, on 4 March 2026.

Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. Until a filing is published, the market cannot know about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.

Across the 517 companies tracked on its exchange, the median is 2 filings; at 4 filings, this issuer sits above that mark. Our records for Jiangsu Yahong Meditech Co., Ltd. go back to 2024, with 4 purchases and 4 sales on the open market in total.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Insider Decl.
8
Thresholds
n/a
Buy Volume
€156,678
4 ops. · all time
Sell Volume
€69,620
4 ops. · all time

Who traded when

BuySale
孙巧玲3 sales
吴亮1 sale

Since the insiders bought

  • Filed 19 Apr 2024 · 933 days ago · €116k
    +44.7%
    Entry CN¥5.64 · Close at T+365 CN¥8.16

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 20,196 of 26,914 companies
34.4
score / 100
Value
20
Quality
49
FCF yld-6.6%
Earn yld-6.4%
EV/EBITDA·
ROE-37%
Gross mgn74%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥11.22
Analyst consensus
1 analysts
1.00/5
CN¥15.30Target CN¥15.30(+36%)CN¥15.30
Income statement
RevenueCN¥277.1M
Gross profitCN¥205.2M74% margin
EBITDA-CN¥389.4M-141% margin
Net income-CN¥416.4M-165.5% margin
Valuation
PER (forward)-29.5x
P/Book5.1x
Beta0.27
Balance sheet & cash
Market capCN¥6.4B
Total debtCN¥345.1M
Free Cash Flow-CN¥430.9M
Debt / Equity33%
Profitability & ownership
ROE-36.9%
ROA-17.3%
% insiders40.1%
% institutions2.0%
Last declaration on 21 July 2026
Declarations8 total
  • ▼
    核心技术人员Executives
    135,800 CNY7SSE
    10,000 shares@ CN¥104.813132.1% of flowA股XSHGSSE:273000000973490240
  • ▼
    核心技术人员Executives
    88,095 CNY16SSE
    5,250 shares20.1% of flowA股XSHGSSE:273000000236276800
  • ▼
    核心技术人员Executives
    119,250 CNY22SSE
    9,000 shares100.0% of flowA股XSHGSSE:273000000229705570
  • ▼
    核心技术人员Executives
    209,475 CNY19SSE
    15,750 shares47.8% of flowA股XSHGSSE:273000000229702820
  • ▲
    董事,高级管理人员,核心技术人员Executives
    876,060 CNY14SSE
    155,000 shares73.9% of flowA股XSHGSSE:173000007523398880
    Canonical exit: 18 Jul 2024 (T+90)
  • ▲
    董事,高级管理人员,核心技术人员Executives
    4,349 CNY7SSE
    654 shares0.4% of flowA股XSHGSSE:173000007383578660
    Canonical exit: 9 Jun 2024 (T+90)
  • ▲
    董事,高级管理人员,核心技术人员Executives
    132,000 CNY8SSE
    20,000 shares10.9% of flowA股XSHGSSE:173000007367374080
    Canonical exit: 3 Jun 2024 (T+90)
  • ▲
    董事,高级管理人员,核心技术人员Executives
    178,185 CNY8SSE
    32,575 shares14.8% of flowA股XSHGSSE:173000007328106300
    Canonical exit: 8 May 2024 (T+90)

8 of 8 declarations

About Jiangsu Yahong Meditech Co., Ltd.

亚虹医药 is a company operating in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations